CONNECT WITH US
HealthTech

HealthTech

Outpace ends an ovarian cancer trial; Incyte data impresses at ESMO

Endpoints News logo

Published on

Add as a preferred source on Google
Outpace ends an ovarian cancer trial; Incyte data impresses at ESMO

Out­pace Bio ends cell ther­a­py tri­al: The Seat­tle start­up canned a Phase 1 …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

As­pen and Bam­busa tar­get $135M IPOs; As­traZeneca vs. Take­da in gas­tric can­cer AD­Cs October 26, 2026

A he­pati­tis B hold lift­ed and drug tabled; Ul­tomiris' ac­cel­er­at­ed ap­proval October 22, 2026

Post-Makary FDA wins over in­vestors, but not sci­en­tists or Big Phar­ma: Sig­nal Sur­vey

Arti­va to wind down af­ter two pa­tient deaths in au­toim­mune cell ther­a­py tri­als



Source link

Disclaimer

We strive to uphold the highest ethical standards in all of our reporting and coverage. We TheMorningPulse.fyi want to be transparent with our readers about any potential conflicts of interest that may arise in our work. It's possible that some of the investors we feature may have connections to other businesses, including competitors or companies we write about. However, we want to assure our readers that this will not have any impact on the integrity or impartiality of our reporting. We are committed to delivering accurate, unbiased news and information to our audience, and we will continue to uphold our ethics and principles in all of our work. Thank you for your trust and support.